Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Wei

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Blood|December 16, 2004
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaSuzanne Trudel, Zhi Hua Li, Ellen Wei, et al.
Geohealth|June 19, 2026
Hybrid Supervised-Unsupervised Modeling for Post-Hurricane Private Well Contamination Risk Score Using Empirical Validation and Community-Informed AssessmentJilei Lin, Jennifer Zhang, Ellen Wei, et al.
Blood|February 10, 2006
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cellsSuzanne Trudel, A Keith Stewart, Eran Rom, et al.
The Journal of Experimental Medicine|September 24, 2004
The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascadesYuan Xiao Zhu, Sally Benn, Zhi Hua Li, et al.
Blood|July 20, 2006
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myelomaEsther Masih-Khan, Suzanne Trudel, Carla Heise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134Sheng-Ben Liang, Xiu-Zhi Yang, Young Trieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemiaChristine I Chen, P Leif Bergsagel, Harminder Paul, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Blood|December 16, 2004
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaSuzanne Trudel, Zhi Hua Li, Ellen Wei, et al.
Geohealth|June 19, 2026
Hybrid Supervised-Unsupervised Modeling for Post-Hurricane Private Well Contamination Risk Score Using Empirical Validation and Community-Informed AssessmentJilei Lin, Jennifer Zhang, Ellen Wei, et al.
Blood|February 10, 2006
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cellsSuzanne Trudel, A Keith Stewart, Eran Rom, et al.
The Journal of Experimental Medicine|September 24, 2004
The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascadesYuan Xiao Zhu, Sally Benn, Zhi Hua Li, et al.
Blood|July 20, 2006
MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myelomaEsther Masih-Khan, Suzanne Trudel, Carla Heise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134Sheng-Ben Liang, Xiu-Zhi Yang, Young Trieu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemiaChristine I Chen, P Leif Bergsagel, Harminder Paul, et al.
Pageof 1